Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Springer Nature America, Inc
Online
2018-09-07
DOI
10.1038/s41416-018-0164-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) Robert J. Motzer et al. Journal of the National Comprehensive Cancer Network
- Systemic Therapy for Metastatic Renal-Cell Carcinoma
- (2017) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
- (2017) Nizar M. Tannir et al. Current Oncology Reports
- Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma
- (2016) R. Nadal et al. ANNALS OF ONCOLOGY
- Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy
- (2016) Emiliano Calvo et al. CANCER TREATMENT REVIEWS
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy
- (2016) Thomas Powles et al. EUROPEAN UROLOGY
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma
- (2015) Laurence Albiges et al. EUROPEAN JOURNAL OF CANCER
- Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer patients
- (2015) Thomas Powles et al. EUROPEAN JOURNAL OF CANCER
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting
- (2015) Guillermo de Velasco et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine
- (2014) Anna R Kwilas et al. Journal of Translational Medicine
- Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
- (2013) R J Motzer et al. BRITISH JOURNAL OF CANCER
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started